FDA Approved: SURVANTA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SURVANTA (beractant) submitted by AbbVie Inc., updating the regulatory status of the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Respiratory Distress Syndrome

Drugs mentioned

• SURVANTA (beractant)

Snippet

SUPPL AP for SURVANTA (BERACTANT)